Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Scotiabank

Scotiabank assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) in a research note issued on Friday,Benzinga reports. The brokerage set a "sector perform" rating and a $105.00 price target on the biotechnology company's stock. Scotiabank's price objective indicates a potential upside of 1.91% from the company's previous close.

Other research analysts have also recently issued research reports about the stock. Robert W. Baird dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. HC Wainwright reiterated a "sell" rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Evercore ISI dropped their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. StockNews.com cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a "hold" rating and a $136.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $170.41.

Remove Ads

Sarepta Therapeutics Price Performance

SRPT traded down $2.53 during trading on Friday, hitting $103.03. The company's stock had a trading volume of 1,159,970 shares, compared to its average volume of 906,959. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $9.84 billion, a price-to-earnings ratio of 82.42 and a beta of 0.75. The firm's 50 day moving average price is $114.48 and its two-hundred day moving average price is $121.80. Sarepta Therapeutics has a 12 month low of $99.50 and a 12 month high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 7.70% of the company's stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. CIBC Asset Management Inc lifted its stake in shares of Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock worth $339,000 after buying an additional 86 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after purchasing an additional 100 shares during the last quarter. EP Wealth Advisors LLC increased its stake in shares of Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after purchasing an additional 105 shares during the period. Manchester Capital Management LLC lifted its holdings in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 138 shares during the period. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.